BRIEF published on 10/20/2026 at 07:05, 8 days 2 hours ago Innate Pharma Announces Conference Call on its Portfolio and Finances Conference Call Financial Situation Innate Pharma Immunothérapies Marseille
BRIEF published on 10/20/2026 at 07:05, 8 days 2 hours ago Innate Pharma Annonce une Conférence Téléphonique sur son Portefeuille et ses Finances Conférence Téléphonique Innate Pharma Immunothérapies Marseille Sitution Financière
PRESS RELEASE published on 10/20/2026 at 07:00, 8 days 2 hours ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique pour présenter l'avancée de son portefeuille et sa situation financière du troisième trimestre 2026 Conférence Téléphonique Portefeuille Situation Financière Innate Pharma Avancée
PRESS RELEASE published on 09/17/2026 at 07:00, 1 month 11 days ago Informations privilégiées / Autres communiqués
PRESS RELEASE published on 09/17/2026 at 07:00, 1 month 11 days ago Inside Information / Other news releases
BRIEF published on 09/16/2026 at 22:05, 1 month 11 days ago Innate Pharma and Sobi Partnership Becomes Effective Innate Pharma Lacutamab Sobi Partnership TELLOMAK-3 Study T-cell Lymphoma
BRIEF published on 09/16/2026 at 22:05, 1 month 11 days ago Le partenariat entre Innate Pharma et Sobi entre en vigueur Innate Pharma Lacutamab Partenariat Sobi Étude TELLOMAK-3 Lymphome À Cellules T
BRIEF published on 09/16/2026 at 22:05, 1 month 11 days ago Innate Pharma et Sobi officialisent leur partenariat Partenariat Stratégique Innate Pharma Phase 3 TELLOMAK-3 Sobi Lymphomes T
BRIEF published on 09/16/2026 at 22:05, 1 month 11 days ago Innate Pharma and Sobi formalize their partnership Strategic Partnership Innate Pharma Phase 3 TELLOMAK-3 Sobi T-cell Lymphomas
PRESS RELEASE published on 09/16/2026 at 22:00, 1 month 11 days ago Inside Information / Other news releases Innate Pharma and Sobi partnership becomes effective after meeting closing conditions, triggering USD 75 million payment and commencing TELLOMAK-3 Phase 3 study in Q1 2027 Partnership Innate Pharma Closing Conditions Sobi TELLOMAK-3
Published on 10/28/2026 at 08:00, 1 hour 12 minutes ago Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 6 hours 17 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 6 hours 22 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 9 hours 32 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 9 hours 47 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/28/2026 at 09:05, 7 minutes ago Rivermate recognized as a key provider of EoR solutions in Everest Group's Employer of Record (EoR) Solutions PEAK Matrix® Assessment 2026
Published on 10/28/2026 at 09:00, 12 minutes ago Municipality Finance issues a GBP 30 million tap under its MTN programme
Published on 10/28/2026 at 09:00, 12 minutes ago PFISTERER Kontaktsysteme GmbH improves its sustainability rating and ranks among the top 3 percent of its industry
Published on 10/28/2026 at 08:00, 1 hour 12 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 1 hour 12 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 15 hours 12 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 15 hours 12 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
